Cabometyx – Cabozanitib
Cabometyx (cabozantinib) is a kinase inhibitor.
Cabometyx is specifically indicated for the treatment of patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.
Cabometyx is supplied as tablets for oral administration The recommended dose is 60 mg orally, once daily. Patients should not to eat for at least 2 hours before and at least 1 hour after taking Cabometyx. Do not substitute Cabometyx tablets with cabozantinib capsules.
987total visits,3visits today